Ophthalmologica

Research Article

Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience

Mello Filho P.a · Andrade G.a · Maia A.a · Maia M.a · Biccas Neto L.a · Muralha Neto A.b · Moura Brasil O.c · Minelli E.d · Dalloul C.e · Iglicki M.f

Author affiliations

aDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil
bDepartment of Ophthalmology, Rio de Janeiro State University, Rio de Janeiro, Brazil
cBrazilian Institute of Ophthalmology, Rio de Janeiro, Brazil
dHCLOE Clinic, São Paulo, Brazil
eD’Olhos Hospital, São José do Rio Preto, Brazil
fRetina Private Office, Buenos Aires, Argentina

Keywords: Anti-vascular endothelial growth factorDiabetic macular edemaDrug deliveryVascular endothelial growth factor

Related Articles for ""
Ophthalmologica 2019;241:9–16
https://doi.org/10.1159/000492132

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: March 30, 2018
Accepted: July 13, 2018
Published online: November 08, 2018
Issue release date: December 2018

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 6

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Abstract

Introduction: There are few real-life studies on the intravitreal 0.7-mg dexamethasone implant for the treatment of diabetic macular edema (DME) conducted in Latin America. We aimed to assess the effectiveness and safety of this implant in clinical practice. Methods: Twenty-seven centers from Brazil and one from Argentina provided information on patients with DME treated with Ozurdex. The efficacy outcome variables were best-corrected visual acuity (BCVA) in Snellen and central retinal thickness (CRT). Safety was assessed by the elevation in intraocular pressure (IOP), occurrence of cataracts, and adverse events. Results: A total of 329 eyes (both treated cases and naïve eyes) from 282 patients underwent treatment. The time since diagnosis of DME ranged from 1 to 156 months. The median BCVA was 0.7 logMAR/50 letters at baseline and 0.3 logMAR/70 letters after treatment (both p < 0.001). Median CRT values decreased from 425 µm at baseline to 270 µm after treatment (p < 0.001). Increases in IOP of at least 10 mm Hg were observed in 7.4% of eyes, and 4% of eyes had cataract evolution. No cases of endophthalmitis were reported. Conclusion: These real-life results suggest that the intravitreal dexamethasone implant is effective and safe for eyes with DME.

© 2018 S. Karger AG, Basel



Related Articles:

References

  1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. 2015 [accessed 2017 September 23]. Available from: http://www.idf.org/diabetesatlas.
  2. Bertoldi AD, Kanavos P, França GV, Carraro A, Tejada CA, Hallal PC, et al. Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review. Global Health. 2013 Dec;9(1):62.
    External Resources
  3. Klafke A, Duncan BB, Stevens A, Rosa RS, de Moura L, Malta D, et al. The decline in mortality due to acute complications of diabetes mellitus in Brazil, 1991-2010. BMC Public Health. 2015 Aug;15(1):772.
    External Resources
  4. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al.; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):552–63.
    External Resources
  5. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556–64.
    External Resources
  6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7–16.
    External Resources
  7. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014 Oct;10(10):CD007419.
    External Resources
  8. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan;(1):CD005656.
    External Resources
  9. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 Dec;121(12):2473–81.
    External Resources
  10. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–14.
    External Resources
  11. Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clin Exp Ophthalmol. 2010 Aug;38(6):605–12.
    External Resources
  12. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006 Sep;113(9):1533–8.
    External Resources
  13. Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol. 2015 Jul;9:1321–35.
    External Resources
  14. Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May;15(7):953–9.
    External Resources
  15. Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF; KKESH International Collaborative Retina Study Group. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: Results of the KKESH International Collaborative Retina Study Group. Retina. 2016 Jan;36(1):131–6.
    External Resources
  16. Bonnin S, Dupas B, Sanharawi ME, Perol J, Erginay A, Tadayoni R, et al. Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema. Eur J Ophthalmol. 2015 Sep-Oct;25(5):448–53.
    External Resources
  17. Gupta PC, Ram J. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond). 2016 Dec;30(12):1650.
    External Resources
  18. Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2015;233(3-4):169–75. Spanish.
    External Resources
  19. Jiménez-Gómez B, González-Montpetit M, Fonollosa Calduch A, Orive Bañuelos A, Valsero Franco S. [Effects of ozurdex on intraocular pressure. A real life clinical practice study]. Arch Soc Esp Oftalmol. 2015 Sep;90(9):421–5.
    External Resources
  20. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol. 2015 Jul;9:1255–68.
    External Resources
  21. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004 Feb;30(2):287–90.
    External Resources
  22. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010 Jul-Aug;30(7):1046–50.
    External Resources
  23. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141–6.
    External Resources
  24. Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular Edema. Ophthalmologica. 2015;233(3-4):176–85.
    External Resources
  25. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.
    External Resources
  26. Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmol. 2012 Feb;90(1):56–60.
    External Resources
  27. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008 Jan;92(1):76–80.
    External Resources
  28. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 Mar;372(13):1193–203.
    External Resources
  29. Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol. 2016 Dec;172:72–9.
    External Resources
  30. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016 Aug;134(8):888–96.
    External Resources
  31. Querques G, Darvizeh F, Querques L, Capuano V, Bandello F, Souied EH. Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France. J Ocul Pharmacol Ther. 2016 Jul-Aug;32(6):383–9.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: March 30, 2018
Accepted: July 13, 2018
Published online: November 08, 2018
Issue release date: December 2018

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 6

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2019, Vol.241, No. 1

December 2018

Article

Recommend This
TOP